PMID- 12931248
OWN - NLM
STAT- MEDLINE
DCOM- 20040505
LR  - 20061115
IS  - 0268-3369 (Print)
IS  - 0268-3369 (Linking)
VI  - 32 Suppl 1
DP  - 2003 Aug
TI  - New strategies for allogeneic BMT.
PG  - S73-5
AB  - In humans, the success rate of BMT across major histocompatibility complex (MHC) 
      barriers is lowered by graft-versus-host disease (GvHD), graft rejection and 
      incomplete T-cell recovery. To prevent GvHD, we attempted to minimize the 
      contamination of bone marrow cells (BMCs) with T cells from the peripheral blood 
      when donor BMCs were collected, finally establishing a new 'Perfusion Method' 
      using cynomolgus monkeys. There was significantly less contamination of BMCs with 
      T cells in this method (<6%) than in the conventional 'Aspiration Method' (>20%) 
      consisting of multiple aspirations of BMCs from the iliac crest. Using 
      radio-sensitive and chimerism-resistant MRL/lpr mice, we also established a new 
      method for allogeneic (allo) BMT and organ allografts. In this method, whole 
      BMCs, containing a small number of T cells and mesenchymal stem cells (MSCs), 
      were directly injected into the bone marrow cavity (intrabone marrow [IBM]-BMT). 
      MRL/lpr mice treated with IBM-BMT survived more than 2 years without showing the 
      symptoms of autoimmune diseases. IBM-BMT thus has several advantages: (i) no GvHD 
      develops even if T cells are not depleted from BMCs; (ii) no graft failure occurs 
      even if the dose of radiation as the conditioning regimen for allo BMT is reduced 
      to 5Gy x 2; (iii) hemopoietic recovery is rapid; and (iv) the restoration of 
      T-cell functions is quick and complete even in donor-recipient combinations 
      across MHC barriers. We believe that these strategies for allo BMT and organ 
      allografts herald a new era in transplantation, and that they would be helpful in 
      allogeneic HSCT of autoimmune diseases.
FAU - Ikehara, S
AU  - Ikehara S
AD  - First Department of Pathology, Transplantation Center, Regeneration Research 
      Center for Intractable Diseases, Kansai Medical University, Moriguchi City, 
      Osaka, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
SB  - IM
MH  - Animals
MH  - Autoimmune Diseases/mortality/*therapy
MH  - Bone Marrow Transplantation/*methods/mortality
MH  - Regeneration
MH  - Skin Transplantation/methods
MH  - Survival Rate
MH  - Transplantation, Homologous
MH  - Treatment Outcome
EDAT- 2003/08/22 05:00
MHDA- 2004/05/07 05:00
CRDT- 2003/08/22 05:00
PHST- 2003/08/22 05:00 [pubmed]
PHST- 2004/05/07 05:00 [medline]
PHST- 2003/08/22 05:00 [entrez]
AID - 1703948 [pii]
AID - 10.1038/sj.bmt.1703948 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2003 Aug;32 Suppl 1:S73-5. doi: 10.1038/sj.bmt.1703948.